Biomarkers of cardiotoxicity in multiple myeloma
Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL
HDACs in multiple myeloma: potential benefits in maintenance phase
Overview of RESONATE-2 clinical trial of ibrutinib in CLL
John Gribben et al.
Overview of new combinaton therapies in acute myeloid leukemia (AML)
Naval G. Daver